159 related articles for article (PubMed ID: 12949782)
1. Hprt(CAG)146 mice: age of onset of behavioral abnormalities, time course of neuronal intranuclear inclusion accumulation, neurotransmitter marker alterations, mitochondrial function markers, and susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Tallaksen-Greene SJ; Ordway JM; Crouse AB; Jackson WS; Detloff PJ; Albin RL
J Comp Neurol; 2003 Oct; 465(2):205-19. PubMed ID: 12949782
[TBL] [Abstract][Full Text] [Related]
2. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
3. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
4. The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH(2)-MPTP).
Numis AL; Unger EL; Sheridan DL; Chisnell AC; Andrews AM
Mol Pharmacol; 2004 Sep; 66(3):718-27. PubMed ID: 15322265
[TBL] [Abstract][Full Text] [Related]
5. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
[TBL] [Abstract][Full Text] [Related]
6. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
[TBL] [Abstract][Full Text] [Related]
7. CAG repeat disorder models and human neuropathology: similarities and differences.
Yamada M; Sato T; Tsuji S; Takahashi H
Acta Neuropathol; 2008 Jan; 115(1):71-86. PubMed ID: 17786457
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
Staal RG; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000
[TBL] [Abstract][Full Text] [Related]
9. Selective alterations of gene expression in mice induced by MPTP.
Xu Z; Cawthon D; McCastlain KA; Slikker W; Ali SF
Synapse; 2005 Jan; 55(1):45-51. PubMed ID: 15499605
[TBL] [Abstract][Full Text] [Related]
10. Embryonic stem cells expressing expanded CAG repeats undergo aberrant neuronal differentiation and have persistent Oct-4 and REST/NRSF expression.
Lorincz MT; Detloff PJ; Albin RL; O'Shea KS
Mol Cell Neurosci; 2004 May; 26(1):135-43. PubMed ID: 15121185
[TBL] [Abstract][Full Text] [Related]
11. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism.
Faherty CJ; Raviie Shepherd K; Herasimtschuk A; Smeyne RJ
Brain Res Mol Brain Res; 2005 Mar; 134(1):170-9. PubMed ID: 15790541
[TBL] [Abstract][Full Text] [Related]
12. Sharing of polyglutamine localization by the neuronal nucleus and cytoplasm in CAG-repeat diseases.
Yamada M; Tan CF; Inenaga C; Tsuji S; Takahashi H
Neuropathol Appl Neurobiol; 2004 Dec; 30(6):665-75. PubMed ID: 15541006
[TBL] [Abstract][Full Text] [Related]
13. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia.
Fisher BE; Petzinger GM; Nixon K; Hogg E; Bremmer S; Meshul CK; Jakowec MW
J Neurosci Res; 2004 Aug; 77(3):378-90. PubMed ID: 15248294
[TBL] [Abstract][Full Text] [Related]
14. Region-specific targeting of dopamine D2-receptors and somatodendritic vesicular monoamine transporter 2 (VMAT2) within ventral tegmental area subdivisions.
Pickel VM; Chan J; Nirenberg MJ
Synapse; 2002 Aug; 45(2):113-24. PubMed ID: 12112404
[TBL] [Abstract][Full Text] [Related]
15. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse.
Ordway JM; Tallaksen-Greene S; Gutekunst CA; Bernstein EM; Cearley JA; Wiener HW; Dure LS; Lindsey R; Hersch SM; Jope RS; Albin RL; Detloff PJ
Cell; 1997 Dec; 91(6):753-63. PubMed ID: 9413985
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
[TBL] [Abstract][Full Text] [Related]
17. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter.
Speciale SG; Liang CL; Sonsalla PK; Edwards RH; German DC
Neuroscience; 1998 Jun; 84(4):1177-85. PubMed ID: 9578404
[TBL] [Abstract][Full Text] [Related]
18. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.
Jenkins BG; Andreassen OA; Dedeoglu A; Leavitt B; Hayden M; Borchelt D; Ross CA; Ferrante RJ; Beal MF
J Neurochem; 2005 Oct; 95(2):553-62. PubMed ID: 16135087
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.
German DC; Liang CL; Manaye KF; Lane K; Sonsalla PK
Neuroscience; 2000; 101(4):1063-9. PubMed ID: 11113355
[TBL] [Abstract][Full Text] [Related]
20. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y
Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
